SOURCE: Given Imaging

May 18, 2006 17:44 ET

Given Imaging Announces PillCam™ Capsule Endoscopy Studies to Be Presented at Digestive Disease Week 2006

YOQNEAM, ISRAEL -- (MARKET WIRE) -- May 18, 2006 -- Digestive Disease Week® 2006 Booth 644 -- Given Imaging (NASDAQ: GIVN) announced today that 86 abstracts on PillCam capsule endoscopy will be presented at this year's Digestive Disease Week® 2006 (DDW®) medical meeting from May 20 to 25 in Los Angeles. Given Imaging will host several educational "Meet the Experts" sessions throughout the week at booth number 644.

Among the clinical data to be presented on PillCam capsule endoscopy are:

Iron Deficiency Anemia

--  "Comparison of Wireless Video Small Bowel Capsule Endoscopy (CE) and
    Upper Endoscopy (EGD) in Evaluation of Iron-deficiency Anemia (IDA) in
    Patients with Negative Colonoscopy," (Abstract M1301) Monday, May 22, 2006,
    8:00 a.m. West Hall A (Los Angeles Convention Center
Clinical Practice/Outcomes
--  "Capsule Endoscopy Findings and Clinical Outcomes in Patients with
    Obscure Gastrointestinal Bleeding," (Abstract S1463) Sunday, May 21, 2006,
    8:00 a.m. West Hall A (Los Angeles Convention Center)
--  "Capsule Endoscopy: Benefit in Evaluation of 'Missed' Endoscopic
    Lesions in Obscure GI bleeding," (Abstract M1247) Monday, May 22, 2006,
    8:00 a.m. West Hall A (Los Angeles Convention Center)
--  "Impact of Capsule Endoscopy on Clinical Outcomes," (Abstract M1323);
    Monday, May 22, 2006, 8:00 a.m. West Hall A (Los Angeles Convention Center)
--  "Capsule Endoscopy for Obscure Gastrointestinal Bleeding: A Report of
    100 Consecutive Cases to Investigate Long Term Clinical Outcomes,"
    (Abstract M1259); Monday, May 22, 2006, 8:00 a.m. West Hall A (Los Angeles
    Convention Center)
--  "Long Term Follow-up of Patients with Obscure Gastrointestinal
    Bleeding after Negative Endoscopy," (Presentation # 500) Tuesday, May 23,
    2006, 9:30 a.m. 511 A/B/C (Los Angeles Convention Center
Crohn's Disease
--  "Mucosal Healing in the Small Intestine Detected by Wireless Capsule
    Endoscopy," (Abstract S1407) Sunday, May 21, 2006, 8:00 a.m. West Hall A;
    (Los Angeles Convention Center)
--  "Usefulness of the Capsule Endoscopy in the Study of Inflammatory
    Bowel Disease: Preliminary results," (Abstract T1122) Tuesday, May 23,
    2006, 8:30 a.m. West Hall A (Los Angeles Convention Center)
Given Imaging will also host teleconference on Friday, May 26th at 10:30 am ET to summarize the key abstracts presented at this year's DDW. To participate in the teleconference, please dial 800-289-0572 fifteen minutes before the conference begins. International callers should dial 913-981-5543. The call will also be webcast live at A replay of the call will be available on the company's website by dialing 888-203-1112. International callers should dial 719-457-0820. The replay participant code is 8747793.

About Digestive Disease Week

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 20-25, 2006 in Los Angeles, at the Los Angeles Convention Center. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit

About Given Imaging

Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company is developing a complete line of PillCam™ video capsules for detecting disorders of the gastrointestinal tract. The company's technology platform is the Given® System, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient. The PillCam SB capsule is a naturally ingested method for direct visualization of the entire small intestine. It is currently marketed in the United States and in more than 50 other countries and has benefited more than 340,000 patients worldwide. The PillCam ESO video capsule, which provides visual examination of the esophagus, has been cleared for marketing by the FDA. Additional capsules for visualization of the stomach and colon are under development. Given Imaging's headquarters, manufacturing, and R&D facilities are located in Yoqneam, Israel; it has direct sales and marketing operations in the United States, Germany and France, and local offices in Japan, Spain, and Australia. For more information, visit

This press release contains forward-looking statements about Given Imaging, including projections about our business and our future revenues, expenses and profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the impact of the newly adopted SFAS 123R for expensing option-based payments, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities and Exchange Commission.

Contact Information